Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Nutrition and Pharmacological Algorithm for Oncology Patients Study

Phase 4

Terminated

Conditions: Quality of Life
Pancreatic Cancer
Nutrition Poor
Head and Neck Cancer
Lung Cancer
Oncologic Complications

Interventions: Behavioral: Nutrition Intervention
Drug: Dexamethasone
Drug: Dronabinol
Drug: Mirtazapine

First Posted Date: 2019-11-07

Last Posted Date: 2022-11-16

Lead Sponsor: Montefiore Medical Center

Target Recruit Count: 1

Registration Number: NCT04155008

Locations: 🇺🇸
Montefiore Hospital, Bronx, New York, United States

Erector Spinae Plane Block Versus Conventional Analgesia in Complex Spine Surgery

Phase 4

Completed

Conditions: Opioid Use
Pain, Postoperative

Interventions: Drug: Bupivacaine
Other: Saline
Drug: Dexamethasone

First Posted Date: 2019-11-07

Last Posted Date: 2024-12-27

Lead Sponsor: Hospital for Special Surgery, New York

Target Recruit Count: 46

Registration Number: NCT04156581

Locations: 🇺🇸
Hospital for Special Surgery, New York, New York, United States

Sphenopalatine Blockade Versus Clinical Treatment

Not Applicable

Conditions: Headache, Post-Dural Puncture

Interventions: Drug: Dypirone
Drug: Ketoprofen
Procedure: Sphenopalatine block
Drug: Gabapentin
Drug: Dexamethasone
Drug: Theophylline
Dietary Supplement: Espresso coffee

First Posted Date: 2019-11-04

Last Posted Date: 2019-11-04

Lead Sponsor: University of Sao Paulo General Hospital

Target Recruit Count: 45

Registration Number: NCT04148846

Locations: 🇧🇷
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Radiation: IGRT 45 Gy in 5 fractions of 9 Gy
Radiation: IGRT 24 Gy single dose
Drug: Dexamethasone
Drug: Tamsulosin

First Posted Date: 2019-11-01

Last Posted Date: 2024-06-11

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 30

Registration Number: NCT04147806

Locations: 🇺🇸
Montefiore Medical Center - Moses Campus, Bronx, New York, United States

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Lenalidomide
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2019-10-25

Last Posted Date: 2024-10-09

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 57

Registration Number: NCT04140162

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
University of Texas Southwestern -- Simmons Comprehensive Cancer Center, Dallas, Texas, United States
🇺🇸
University of Rochester, Rochester, New York, United States

and more 1 locations

Ultrasound-Guided Treatments for Shoulder Pain in Wheelchair Users With Spinal Cord Injury

Phase 2

Recruiting

Conditions: Spinal Cord Injuries
Shoulder Pain
Tendinopathy
Rotator Cuff Tears

Interventions: Device: Lipogems
Drug: Dexamethasone

First Posted Date: 2019-10-23

Last Posted Date: 2022-10-14

Lead Sponsor: Kessler Foundation

Target Recruit Count: 24

Registration Number: NCT04136743

Locations: 🇺🇸
Kessler Foundation, West Orange, New Jersey, United States

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: JNJ-68284528
Drug: Lenalidomide
Drug: Daratumumab
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2019-10-21

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 237

Registration Number: NCT04133636

Locations: 🇺🇸
Virginia Commonwealth University - Massey Cancer Center, Richmond, Virginia, United States
🇺🇸
University Of California San Diego, San Diego, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 43 locations